TNF-alpha inhibitors associated with uveal melanoma
the ONA take:
According to new findings reported in the journal Mayo Clinic Proceedings, researchers warn that there may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
The researchers report three cases of uveal melanoma that occurred after patients were treated with TNF-alpha inhibitors. Two of the patients were treated at Mayo Clinic in Rochester, Minnesota, and the other was treated at Yale-New Haven Hospital in New Haven, Connecticut. All three, two women and one man, were treated for inflammatory disease with TNF-alpha inhibitors.
This class of drugs include adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, and they are used to treat inflammatory bowel disease, psoriasis, and rheumatoid arthritis. In the cases reported, the two women were treated for inflammatory bowel disease and developed rapidly growing melanocytic tumors within 1 year of TNF-alpha inhibitor initiation.
The male patient was treated for rheumatoid arthritis and developed a uveal melanoma within 16 months of TNF-alpha inhibitor therapy.
The researchers suggest that there is an association between TNF-alpha inhibitors and cutaneous melanoma and recommend that patients planning to initiate TNF-alpha inhibitor therapy have an eye exam before beginning therapy. If patients have preexisting nevi, they should be monitored with eye examinations at regular intervals during therapy.
There may be a correlation between TNF-alpha inhibitors and the development of uveal melanoma.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|